Winter 2017/18 Teasers
Drug Discovery World
Discovery and development of inhaled biopharmaceuticals - The impact and effective routes of non-clinical safety assessment of inhaled biopharmaceuticals
By Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall

With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in automation has never been greater in terms of helping the drug discovery community as a whole.

The creation and subsequent development of inhaled biologics has become highly significant as it is now the route of choice for the delivery of numerous drugs. This is especially the case with biopharmaceuticals developed for the treatment of respiratory diseases....

You just need to REGISTER - its FREE - to read the rest of this article straight away.